MYCN and neuroblastoma: A stringent test of whether MYCN destabilization is a viable therapeutic strategy for MYCN-driven cancers is to establish whether murine tumors genetically-engineered to overexpress MYCN, together with primary human neuroblastoma tissue amplified for MYCN, are targeted in vivo.